[225AC]-SNA014

N/A

Report date: 2025/11/17 17:57:30

Base Information

Drug Name[225AC]-SNA014

Drug Alias Name[225AC]-SNA-014

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug ConjugatesRadiation-emitting products > Nuclides > Actinium > 225Ac

Mechanisms of ActionPositron-emission tomography enhancersClaudin 18 protein modulatorsDiagnostic imaging enhancers +[4]

TargetsClaudin-18 splice variant 2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesSmartnuclide Biopharma

China Registration ClassN/A

Develop Information

Active CompaniesSmartnuclide Biopharma

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A